Logo

AbbVie Acquire TeneoOne and its TNB-383B for the Treatment of Relapsed or Refractory Multiple Myeloma

Share this

M&A

AbbVie Acquire TeneoOne and its TNB-383B for the Treatment of Relapsed or Refractory Multiple Myeloma

Shots:

  • AbbVie exercised its exclusive right to acquire TeneoOne and its TNB-383B based on an interim analysis of an ongoing P-I study that demonstrated ORR (79%)- VGPR (63%)- CR (29%) at doses ≥40 mg in the dose-escalation cohorts with a median follow-up time of 6.1 mos.- m-DOR has not been reached
  • In Feb’2019- AbbVie and TeneoOne collaborated to develop & commercialize TNB-383B that targets BCMA and CD3 & designed to direct the body immune system to kill BCMA-expressing tumor cells
  • Abbvie will use Teneobio’s anti-CD3 platform to assess its clinical validation. At RP2D of TNB-383B (60 mg- q3w- IV) for MM showed a 67% CRS rate in all grades

  | Ref: PR Newswire | Image: abbvie

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions